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AINTRODUCTION
Adenoviruses (Ads) contain more than 20 genes ded-
icated to control various aspects of the innate or ac-
quired immune responses of the infected host. Some of
these functions are not necessary for the successful
replication of the virus in cultured cells; however, they
appear to target processes that are essential for the
survival of virus during acute or latent infection in vivo
(reviewed in Lukashok and Horwitz, 1997; Shenk, 1996;
Wold et al., 1999). Many of these immunoregulatory
genes are clustered in early region 3 (E3), which con-
tains NF-kB-binding sites in the E3 promoter (Deryckere
and Burgert, 1996). Proteins encoded in the E3 region
can inhibit peptide presentation by class I MHC and cell
death by TNFa-, Fas-, or TRAIL-induced mechanisms of
cytolysis (Wold et al., 1999). Since the activity of the
NF-kB transcription factor is enhanced after stimulation
f the TNFa signal transduction pathway, the E3 genes
hould be activated during the inflammatory response.
The focus of this minireview is on two areas of re-
earch: (1) A progress report on the nature and function
f the cell proteins that interact with one of the Ad E3
roteins (14.7K), an inhibitor of TNFa-induced cytolysis;
and (2) the use of the immunoregulatory Ad E3 genes in
murine models in vivo to reduce the immune responses
to allogeneic islet transplantation and to prevent islet
destruction during the autoimmune response that results
in type I or insulin-dependent diabetes mellitus (IDDM).
There are excellent recent reviews about other aspects
of the E3 proteins and other adenoviral proteins that
regulate the interferon response, cell death, and the cell
cycle (Mahr and Gooding, 1999; Wold et al., 1999).
Because viruses have evolved as intracellular para-
sites over millions of years, they have finely tuned the
process of acquiring molecules and targeting pathways
to deal with counterattacking host immune responses.I
1 Address correspondence and reprint requests to author. Fax: (718)
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1Using the techniques of modern molecular biology and
genetics, we have attempted to find the host molecules
targeted by the Ad E3-14.7K viral immunoregulatory pro-
tein. In most cases, the host molecules that we identified
were novel and involved signaling pathways that had not
been sufficiently elucidated to easily explain the function
of the Ad E3-14.7K protein. However, as we and others
have contributed to an understanding of these signal
transduction pathways, exciting new observations are
being made. Before the advent of modern cloning tech-
niques, viruses were critical reagents for discovering
and understanding essential cellular processes such as
mRNA splicing (Berget et al., 1977), oncogene function
(van der Eb et al., 1977), and eukaryotic DNA replication
(Challberg and Kelly, 1979; Friefeld et al., 1984). I believe
hat we have returned in part to such an era of discovery
or the study of viral immunoregulatory genes. By deter-
ining cell molecules which are the targets of proteins
uch as Ad E3-14.7K, viruses can help us bring together
he vast amount of knowledge that has been produced
y immunologists and cell and molecular biologists into
oherent immunoregulatory pathways. These pathways,
hich control inflammatory responses, can then be used
herapeutically to control disease processes. In some
ases, the complete mechanistic understanding of the
ignaling pathways targeted by viral proteins will have to
ait for additional data from other areas of biology;
owever, in the interim it will still be possible to use the
iral immunoregulatory proteins in therapeutic or prophy-
actic ways to alter disease processes. This minireview
ill attempt to focus on the results as well as the pro-
esses by which we have pursued these goals of dis-
overy.
DESCRIPTION OF THE ADENOVIRUS E3
IMMUNOREGULATORY PROTEINS
d E3-gp19KAn Ad E3-19kDa glycoprotein (gp19K) retains the class
major histocompatibility complex (MHC) heavy chain in
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2 MINIREVIEWthe endoplasmic reticulum (ER) (Burgert and Kvist, 1985)
and also prevents tapasin processing of peptides that
bind to the class I MHC molecule (Bennett et al., 1999).
he gp19K contains a lysine KKXX (X 5 any amino acid)
otif at its carboxyl end, and this serves to retrieve
roteins from the Golgi back to the ER (Jackson et al.,
993) (see Fig. 1 for transcription and translation map of
enes encoded in the E3 region).
d E3-14.7K
An Ad E3-14.7kDa protein (14.7K) inhibits apoptosis
nduced by TNFa by mechanisms which have not been
fully elucidated; however, 14.7K does not appear to affect
the amounts or distribution of the TNFa receptor. 14.7K
inhibits the synthesis of arachidonic acid induced by
TNFa, a process which could have effects on apoptosis
or the pathway affecting the inflammatory response
(Krajcsi et al., 1996). There is also one report that 14.7K
from Ad type 5 can bind to caspase 8 and inhibit Fas-
induced apoptosis (Chen et al., 1998); however, we have
failed to confirm these interesting observations using the
related protein from Ad2. Our studies on the mechanism
of action of the 14.7K protein will be one of the topics
discussed in this review.
Ad E3-10.4K/14.5K complex (RIDa/b)
FIG. 1. Map of the E3 region. The proteins, whose genes are encoded
mRNAs (arrows) that direct their synthesis. The Ad E3 gp19K, 11.6K (AD
shown as solid rectangles and are discussed further in the text. Alt
rectangles, have been shown to code for proteins, their functions have
transactivated during Ad infection by the Ad E1A protein; however, in t
this transcription region. There are two polyadenylation sites (pA) useA heterotrimer of Ad E3-10.4kDa (10.4K) and Ad E3-
14.5kDa (14.5K) polypeptides also inhibits TNFa and Fasligand-induced cell death by internalizing their receptors
and promoting their degradation in lysosomes (Elsing
and Burgert, 1998; Shisler et al., 1997; Tollefson et al.,
998). The 10.4K and 14.5K proteins have been renamed
IDa and RIDb, respectively, to highlight their function as
mediators of receptor internalization and degradation,
which occur in the lysosomes (Wold et al., 1999).
Ad E3-11.6K (ADP)
All of the E3 proteins described above prevent cell
killing by various mechanisms that either use soluble
ligands such as TNFa or cell-mediated mechanisms of
cell killing such as by cytotoxic T lymphocytes (CTL). In
contrast to the antiapoptotic proteins coded in the E3
region, there is an 11.6-kDa E3 (11.6K) protein, which can
induce cell death (Tollefson et al.,1996). It has been
renamed ADP (adenovirus death protein) and its synthe-
sis appears to be regulated differently than all the others
from the early region 3 promoter. ADP is primarily ex-
pressed late in the virus infectious cycle using an mRNA
not shown in Fig. 1, presumably initiating from the strong
major late promoter that also upregulates the synthesis
of the structural proteins needed in large amounts to
make progeny virus. ADP also has been recognized as a
facilitator of exit of assembled virus from the nucleus. In
the absence of ADP the amounts of normal virus made
E3 region, are shown as rectangles juxtaposed to the family of spliced
K/14.5K (RIDa\b), and 14.7K, for which some functions are known, are
some of the other open reading frames (ORFs), shown as hatched
en elucidated (Wold et al., 1995). The E3 promoter is at the left and is
E3 transgenic animals, the rat insulin promoter is placed upstream of
rious members of the E3 mRNA family.in the
P), 10.4
hough
not behave difficulties in exiting the cell resulting in smaller
plaque size. Adenovirus vectors engineered to overex-
p
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3MINIREVIEWpress ADP and be selectively toxic to tumor cells have
been studied as potentially therapeutic agents for killing
malignant cells (Doronin et al., 2000).
OTHER ADENOVIRUS IMMUNOREGULATORY
PROTEINS AND VA RNA1
There are other Ad proteins coded by genes in the E1B
region that inhibit apoptosis. The E1B-19kDa (19K) is a
homologue of Bcl-2 and binds to proapoptotic members
of this family of proteins residing in mitochondrial mem-
branes (reviewed in Chinnadurai, 1998; White, 1998). The
E1B-19K inhibits release of both Apaf-1 and cytochrome
c following p53 signaling, which prevents Apaf-l and
cytochrome c from binding to procaspase 9 and activat-
ing mechanisms of apoptosis. The E1B-19K can also act
through upstream signals requiring the interactions of
death domain (DD)-containing proteins with the intracel-
lular domains of receptors of death signals (Perez and
White, 1998). Some of the molecules on these pathways
will be described further below (Fig. 2). Another E1B
protein (E1B-55kDa) binds directly to p53 and prevents
its activation of transcription of proapoptotic proteins
(Martin and Berk, 1998). Ads have also evolved the ability
to prevent interferon-induced inhibition of protein synthe-
sis and this function resides in a “viral-associated RNA”
(VA RNA1) itself, which can bind to and inhibit the
FIG. 2. TNF and Fas signal transduction pathway. The important
molecules on the signal transduction pathway that lead to either cell
death or activation of NF-kB, an antiapoptotic signal, are shown. The
controls that drive the pathway toward apoptosis or prevention of cell
death are not completely understood. The TNF receptor and Fas are
shown on the cell surface and the first molecules, TRADD and FADD,
to which they bind are indicated. The interactions of FIP-3 (NEMO\IKKg)
with the “upstream” molecule RIP and the “downstream” molecules
such as IKKa\IKKb are indicated. The latter complex of kinases phos-
horylate IkBa promoting its ubiquination and degradation. This frees
F-kB from its cytoplasmic tether (IkBa) to move into the nucleus and
ncrease transcription from NF-kB-responsive sequences. Ad E3-14.7K,
which binds to FIP-3 and may also bind to caspase 8, reverses the
proapoptotic effect of FIP-3 after transfection.dsRNA-dependent protein kinase (PKR) phosphorylation
of EIF2a (Mathews and Shenk, 1991). Phosphorylation ofthis site ordinarily inhibits the initiation of protein synthe-
sis; however, VA RNA permits viral protein synthesis to
continue in the presence of interferons. There are also
inhibitory effects of the E1A proteins on the activity of
type I interferons and interferon g in the induction of
antiviral genes (Leonard and Sen, 1997). Control of class
I MHC, TNF, or Fas-ligand cytolysis and inhibition of
interferons are targets shared by a variety of viruses, but
the exact step targeted on the each of these pathways
often varies between viruses.
Implications of immunoregulatory proteins in the
virus life cycle
All of these immunoregulatory functions presumably
facilitate the survival of adenoviruses as intracellular
pathogens; however, the absence of a good animal
model for studying human adenovirus pathogenesis has
left these conclusions somewhat tentative (Lukashok
and Horwitz, 1998). Human adenoviruses can enter mu-
rine cells and express early viral genes as well as gene
products controlled by exogenous promoters such as
those introduced in Ads used as gene therapy vectors;
however, human Ads do not complete their replication
cycle in murine cells in vivo or in vitro (Ginsberg et al.,
1991). Ad gene therapy vectors are usually deleted of E3
genes to increase the potential packaging size of the
foreign gene; however, a variety of Ad vectors have been
designed to contain all or parts of the E3 region in
attempts to decrease the immune response to the virus
and prolong the expression of the therapeutic gene
(Bruder et al., 1997; Ilan et al., 1997; Poller et al., 1996).
Ads with various mutations especially in the E3 region
have been studied for altered virulence and pathogenic-
ity in murine models (Ginsberg and Prince, 1994; Sparer
et al., 1996). Changes in the inflammatory response fol-
lowing deletions of individual E3 genes have been dem-
onstrated. Other studies used mice expressing the Ad
E3-14.7K as a transgene under the control of the lung-
specific surfactant C promoter (Harrod et al., 1998). Such
mice, which were infected with Ad E3 deletion mutants,
developed less of an inflammatory response than non-
transgenic littermates because of the presence of the
14.7K as a transgene.
CELL PROTEINS THAT INTERACT WITH THE AD
E3-14.7K
In an attempt to learn more about the molecular mech-
anism of inhibition of apoptosis by the Ad E3-14.7K pro-
tein, it was used as bait in the yeast two-hybrid system to
determine its intracellular interacting targets. Initially,
four 14.7K-interacting proteins (FIPs) were identified by
this procedure, and three have been characterized (Fig.
3) (Li et al., 1997, 1998, 1999). The interactions of each of
the three FIPs with the Ad E3-14.7K protein were con-
firmed within mammalian cells (293 HEK) and by in vitro
ic
w
d
i
s
m
4 MINIREVIEWassays. The three FIPs were each novel proteins, when
first isolated 5 years ago at the outset of these experi-
ments. However, other investigators involved with the
elucidation of specific pathways, such as the signal
transduction pathway affecting NF-kB, have come upon
each of the FIPs independently using totally different
approaches. The following summary of the properties
and functions of the FIPs should be considered a
progress report as many aspects of their function during
adenovirus infection or in normal uninfected cells have
still not been elucidated.
FIP-3 (NEMO or IKKg)
FIP-3 has been the most intensively studied in our
laboratory and by others interested in the NF-kB pathway
of signal transduction. FIP-3 causes a readily apparent
morphologic abnormality after transient transfection of a
variety of cells, which then proceed to apoptosis (Li et al.,
1999). Cell death is delayed and less profound than that
produced by a variety of overexpressed proteins on the
death pathway, such as the TNF receptor (TNF-R). Apo-
ptosis by FIP-3 is reversed by 70% in the presence of Ad
E3-14.7K, suggesting that FIP-3 may be one of the im-
portant targets for the inhibition of cell death by Ad
E3-14.7K. We also demonstrated that FIP-3 interacted
with RIP (receptor-interacting protein), IKKb (inhibitor of
kappa kinase beta), and NIK (NF-kB-inducing kinase) (Li
et al., 1999). These proteins appear to have various key
roles in signaling from TNF-R, through the phosphoryla-
tion, ubiquitination, and degradation of IkBa to activate
NF-kB, which is a well-studied inhibitor of cell death
nduced by TNFa (Beg and Baltimore, 1996; Van Antwerp
et al., 1996). Although it has been shown convincingly
that FIP-3 is an essential component for the activation of
FIG. 3. Interactions of the Ad E3-14.7K protein. The interactions of
14.7K with three FIPs are depicted together with the secondary inter-
actions of the FIPs with other cellular proteins, some of which are
described in the legend to Fig. 2. The three distinct pathways poten-
tially affected by these interactions are indicated.NF-kB, overexpression of FIP-3 by transient transfection
learly inhibits NF-kB reporter plasmids (Li et al., 1999;Rothwarf et al., 1998; Wang et al., 1988; Yamaoka et al.,
1998; Zhang et al., 2000). The essential nature of FIP-3
was first demonstrated by complementation assays in
fibroblasts NEMO (NF-kB essential modulator), the
mouse homologue of FIP-3, was isolated by its ability to
complement the deficiency in NF-kB activity in a mutant
fibroblast cell line (Yamaoka et al., 1998). Another report
described the isolation of a molecule called IKKg, which
as associated with IKKb in a high-molecular-weight
complex and enhanced the kinase activity of IKKb; how-
ever, IKKg had no intrinsic protein kinase activity when
assayed alone (Rothwarf et al., 1998). IKKg is identical to
FIP-3. It is intriguing that observations on the domain
structure of FIP-3 have shown that the IKKb-interacting
omain, which should activate NF-kB by destruction of
the IkBa molecule retaining NF-kB in the cytoplasm, is
separable from the domain that inhibits the activity of
NF-kB after transfection (Ye et al., 2000). The observa-
tions of low levels of FIP-3\NEMO\IKKg being required
for NF-kB activation and higher amounts being inhibitory
have suggested that this molecule may be a molecular
switch for fine regulation of the activity of NF-kB. Al-
though the levels of FIP-3 transcripts in various organs
are quite different, the levels of FIP-3 have not been
shown to be modulated by TNFa or any signal transduc-
tion modulator studied thus far (Li et al., 1999). A recent
report using short peptides representing sequences of
IKKb that interact with FIP-3\NEMO\IKKg has shown that
one peptide inhibits the interaction of these two proteins,
preventing induction of NF-kB but not its basal activity.
When the inhibitory peptide was modified to promote its
entry into cells in vivo, the peptide also decreased the
nflammatory response following two separate noxious
timuli (May et al., 2000). These studies indicate that it
ay be possible to design inhibitors of the NF-kB sig-
naling pathway that will inhibit NF-kB following inflam-
matory stimuli but not interfere with the basal level of
expression, which appears necessary for cell survival.
FIP-2 (NRP)
FIP-2 has domains of homology with FIP-3 and has
also been called NEMO-related protein (NRP), but does
not share any of the functions of the NF-kB regulatory
protein (Li et al., 1998; Schwamborn et al., 2000). FIP-2
also does not cause cell death when overexpressed
following transfection protocols. However, if the apopto-
tic effects of expressing the TNF-R or RIP are inhibited by
Ad E3-14.7K, the addition of FIP-2 causes apoptosis.
Although there has not been a cellular homologue of Ad
E3-14.7K recognized, we have postulated that one may
exist and subsequently be controlled by altering the
amounts of FIP-2. FIP-2 has been shown to be transcrip-
tionally regulated by the addition of TNFa. A potentially
important function for FIP-2 has been suggested by the
demonstration that FIP-2 binds to the polyglutamine
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5MINIREVIEWtracts in abnormal huntingtin protein, the putative patho-
genic molecule identified as the product of the mutated
gene in Huntington’s chorea (Faber et al., 1998). Abnor-
al huntingtin protein is the product of expansion of the
rinucleotide repeat that results in polyglutamine tracts
hat appear to be associated with apoptosis in cells of
euronal origin. The function of FIP-2 and/or Ad E3-14.7K
n preventing cell death induced by huntingtin protein is
urrently being investigated.
IP-1 (Rag-A), GIP-1 (TCTEL), and GIP-2
FIP-1 is a small GTPase isolated in our laboratory also
y using Ad E3-14.7K as bait. FIP-1 is identical to RAG-A
Schurmann et al., 1995), a molecule isolated by probing
ith sequences common to a variety of GTPases. FIP-1
oes not cause cell death but was shown to bind to a
ariety of phosphorylated proteins upon stimulation with
NFa (Li et al., 1997). Because we anticipated that FIP-1
ay require other proteins to learn about its function, we
sed it as bait in the yeast two-hybrid system and iso-
ated two new interesting cell proteins. The first is a
omponent we initially called GIP-1 (GTPase-interacting
rotein); however, it is identical to TCTEL, a 14-kDa
omponent of the microtubule motor protein dynein
Campbell et al., 1998; Lukashok et al., 2000). In the
presence of the bridging protein FIP-1, a ternary com-
plex can form between Ad E3-14.7K and TCTEL. FIP-1
can bind to each of the other two components sepa-
rately. We have been searching for the functional sig-
nificance of an early Ad protein binding to a compo-
nent of the microtubule motor dynein. Microtubules
have been shown to be important in the transport of
the adenovirus particle from the endocytic vesicle
across the cytoplasm to the nucleus during the pro-
cess of viral entry (Luftig and Weihing, 1975). However,
Ad E3-14.7K is not believed to be a structural compo-
nent of the virion, as it is only made after the viral DNA
has entered the nucleus and been transcribed to make
the early viral proteins. We are currently conducting
experiments in vitro to determine if Ad E3-14.7K can
affect the function of dynein in moving the virus toward
the minus (nuclear membrane) end of the microtu-
bules. It is also possible that the Ad E3-14.7K protein
could affect exit of the virus from the nucleus after new
progeny virus is made. As described above, the Ad
E3-11.6K protein has been shown to be involved in exit
of the virus from the nucleus (Tollefson et al., 1996).
Perhaps the 14.7K protein might facilitate the transport
of viral particles in the cytoplasm from the vicinity of
the nucleus to the plasma membrane along microtu-
bules in a mirror image process to that involved in viral
entry; however, this is a speculation that awaits ex-
perimental verification as little is known about the
mechanism of adenovirus exit from the cell.
A second protein that we discovered using FIP-1(RagA) as bait in the yeast two-hybrid system was an-
other small GTPase that we named GIP-2 (Accession no.
AF323609; Lukashok, S. A., Buntzman, A. S., Ye, J. and
Horwitz, M. S., personal observations). GIP-2 has struc-
tural similarities to the Saccharomyces cerevisiae Gtr2,
and FIP-1 has structural similarities to the yeast Gtr1
(Nakashima et al., 1999). FIP-1 and GIP-2 differ from other
small GTPases but are sufficiently similar to each other
to be classified as a new GTPase family in a dendrogram
analysis of small GTPases. Loss of function (lof) muta-
tions either in Gtr1 or Gtr2 reversed the temperature-
dependent growth defect of mutations in RCC1, a protein
that has been shown to be important in the formation of
the centrosomes of the mitotic spindle as well as in
nuclear-cytoplasm transport of macromolecules (Hirose
et al., 1998, Nakashima et al., 1999). In addition, the
RNA of the mouse homologue of human GIP-2 appears
o be over-expressed in metastatic cells (Nakaji et al.,
999). The effects of Ad E3-14.7K on the function of GIP-2
n these processes have not yet been investigated. Thus,
here is a fertile area for further investigation to deter-
ine whether the adenovirus protein can affect micro-
uble-based processes such as centrosome function and
etastases.
ADENOVIRUS E3 PROTEINS FACILITATE
ALLOGENEIC ISLET SURVIVAL AFTER
TRANSPLANTATION AND PREVENT AUTOIMMUNE
DIABETES IN MURINE MODELS
llogeneic transplantation of islets
We postulated that the Ad immunoregulatory genes
ould be used therapeutically or prophylactically under
ther conditions for which the goals of downregulating
he immune system would be beneficial. Two conditions,
revention of tissue rejection after allogeneic transplan-
ation and tissue damage after autoimmunity, were cho-
en to prove the principles proposed. For these experi-
ents, the entire Ad E3 cassette was introduced as a
ransgene controlled by the rat insulin promoter. Islets
ere used as targets because they are easy to isolate
nd have readily measured functional properties. In ad-
ition, success with these experiments might benefit a
arge number of patients with type I diabetes. Trans-
lanted donor islets containing the H-2bxd class I major
histocompatibility complex (MHC) and expressing the Ad
E3 transgenes demonstrated long term acceptance in
allogeneic H-2d recipients (Efrat et al., 1995). The studies
have been extended to islet transplantation from BALB
H-2k congenic donors to H-2d recipients with similar
effects (Efrat and Horwitz, personal observation); how-
ever, some combinations such as H-2d donors into H-2b
recipients were rejected even in the presence of Ad E3
expression in donor b cells. The explanation for the
selectivity of successful transplantation is not completely
understood, although it has been known for a long time
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6 MINIREVIEWfrom the work of others that the Ad2 E3-gp19K protein
interacts preferentially with H-2Db and Kd, and neither of
the H-2k Class I alleles binds well to the viral protein
(Wold et al., 1999). However, more recent data showing
hat the gp19K protein inhibits tapasin, in a process that
oes not depend on MHC haplotypes, may explain the
uccess with H-2k as donor transplants and the more
general inhibition of transplant rejection.
Prevention of Diabetes in Two Mouse Models
The studies incorporating Ad E3 genes targeted for
expression in b cells were extended to well-established
models of autoimmune diabetes. The original transgenic
founders carrying E3 genes were mated with animals
that readily develop type I autoimmune diabetes.
Lymphocytic Choriomeningitis Viral Proteins as
Transgenic Targets for the Induction of Islet
Destruction
One of the models was created in the Oldstone labo-
ratory by also using the transgenic technique in which
either of two lymphocytic choriomeningitis virus (LCMV)
proteins (NP or GP) was expressed under the control of
the rat insulin promoter for targeted expression in pan-
creatic b cells (Oldstone et al., 1991). These LCMV trans-
genic animals remain euglycemic until infected with
LCMV, whereupon they develop a full immune response
to the virus and its proteins. This antiviral response
targets the LCMV protein expressed at very low levels on
the surface of b cells and destroys them in an immune
response that requires both CD4 and CD8 cells when the
NP is the target, but only CD8 cells when GP is targeted
(von Herrath et al., 1997). The presence of RIP-E3 com-
pletely prevented the onset of diabetes when LCMV-NP
or -GP were expressed in the same islets. All of these
animals had been previously backcrossed with H-2b an-
mals to eliminate any differences of MHC in the inter-
retation of these experiments. It appears that spleno-
ytes even in animals carrying the Ad E3 genes were
ormally primed to recognize LCMV targets but they
ere prevented from targeting the islets in vivo in the
resence of the Ad E3 transgene.
OD Mice
The second model of diabetes in which the Ad E3
ransgenes were tested for effects was the nonobese
iabetic mouse (NOD). The same Ad E3 founder used for
revious experiments was extensively backcrossed to
OD mice for greater than eight generations, and the 15
hromosomal regions recognized as essential for the
nduction of diabetes in NOD had been reconstituted as
easured by microsatellite analysis in the NOD-E3 ani-
als. Preliminary results indicate that expression of Ad
3 transgenes in pancreatic islets does protect NODice from diabetes, and the mechanisms responsible
re currently being evaluated (Efrat et al., submitted).
FUTURE DIRECTIONS
The proof of principle that Ad E3 genes and proteins
an be used to prevent diabetes and facilitate allogeneic
ransplantation has been achieved. However, the system
eeds to be optimized. Thus far, we have been able to
ither prevent allogeneic transplant rejection or autoim-
une destruction of islets but not been able to prevent
oth of these immune reactions simultaneously. For
hese techniques to be used to create a human islet cell
ine that could be used to treat type I diabetes, both parts
f this immune reaction must be controlled. The attrac-
ion of this way of approaching the therapy of diabetes is
hat success in using such an islet line would not require
ystemic immunosuppression with the attendant difficul-
ies of opportunistic infections and increased suscepti-
ility to malignancies. Progress in the creation of human
ell lines secreting appropriate amounts of insulin in
esponse to glucose is being made. In addition, the
ntroduction of E3 genes even into primary human islets
an be achieved using Ad vectors (Leibowitz et al., 1999).
y understanding which E3 genes are responsible for
he beneficial effects in vivo, it may be possible to opti-
ize the expression of a more limited number of Ad E3
enes than in the current protocols. Such experiments
n selected deletions of individual E3 proteins are un-
erway in both the NOD and LCMV murine models. We
lso have postulated that removal of the only death
rotein (ADP) in this region will promote the beneficial
ffects of E3 on decreasing the immune response to
arget cells expressing these genes. Since there are
ore than 50 human adenoviruses, it is also possible
hat serotypes other than group C (Ad types 2 and 5)
sed in these experiments may have E3 regions that will
e more optimal for immune regulation.
The use of FIP-1 and 14.7K to understand the function
f dynein as a microtubule motor during adenovirus
nfection will be pursed. The potential for altering hun-
ingtin-induced apoptosis with FIP-2 and 14.7K will be
tudied in cultured cells derived from selected regions of
he central nervous system. Wild-type huntingtin has
een shown to be essential for normal development and
revention of apoptosis (Rigamonti et al., 2000), but mu-
ant huntingtin protein may be amenable to functional
orrection with the combination of FIP-2 and 14.7K. The
nderstanding of the interaction of FIP-3\NEMO\IKKg
with other proteins on the NF-kB pathway and the selec-
tive inhibition of these interactions with peptides or small
molecules may be useful for the control of inflammation
under a variety of conditions including the autoimmunity
of diabetes, rheumatoid arthritis, and systemic lupus
erythematosus. For a more complete understanding of
the mechanism of action of the Ad E3 proteins, studies
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7MINIREVIEWsimilar to those which produced 14.7K-interacting pro-
teins are also underway to isolate the cell proteins that
bind to the 10.4K/14.5K (RID) viral proteins.
ACKNOWLEDGMENTS
I acknowledge critical reading of the manuscript and helpful sug-
gestions from Matthew D. Scharff, Jianjiang Ye, Adam S. Buntzman,
Jayne Gilbert, David Serreze, and Joshua Friedman. The work reviewed
in the manuscript was supported by NIH Grants DK-52956, CA72963,
AI42295, and CA13330.
REFERENCES
Beg, A. A., and Baltimore, D. (1996). An essential role for NF-kappaB in
preventing TNF-alpha-induced cell death [see comments]. Science
274, 782–784.
Bennett, E. M., Bennink, J. R., Yewdell, J. W., and Brodsky, F. M. (1999).
Cutting edge: Adenovirus E19 has two mechanisms for affecting
class I MHC expression. J. Immunol. 162, 5049–5052.
Berget, S. M., Moore, C., and Sharp, P. A. (1977). Spliced segments at
the 59 terminus of adenovirus 2 late mRNA. Proc. Natl. Acad. Sci. USA
74, 3171–3175.
ruder, J. T., Jie, T., McVey, L., and Kovesdi, I. (1997). Expression of
gp19K increases the persistence of transgene expression from an
adenovirus vector in the mouse lung and liver. J. Virol. 71, 7623–7628.
urgert, H. G., and Kvist, S. (1985). An adenovirus type 2 glycoprotein
blocks cell surface expression of human histocompatibility class I
antigens. Cell 41, 987–997.
ampbell, K. S., Cooper, S., Dessing, M., Yates, S., and Buder, A. (1998).
Interaction of p59fyn kinase with the dynein light chain, Tctex-1, and
colocalization during cytokinesis. J. Immunol. 161, 1728–1737.
hallberg, M. D., and Kelly, T. J., Jr. (1979). Adenovirus DNA replication
in vitro. Proc. Natl. Acad. Sci. USA 76, 655–659.
hen, P., Tian, J., Kovesdi, I., and Bruder, J. T. (1998). Interaction of the
adenovirus 14.7-kDa protein with FLICE inhibits Fas ligand-induced
apoptosis. J. Biol. Chem. 273, 5815–5820.
hinnadurai, G. (1998). Control of apoptosis by human adenovirus
genes. Semin. Virol. 8, 399–408.
eryckere, F., and Burgert, H. G. (1996). Early region 3 of adenovirus
type 19 (subgroup D) encodes an HLA-binding protein distinct from
that of subgroups B and C. J. Virol. 70, 2832–2841.
oronin, K., Toth, K., Kuppuswamy, M., Ward, P., Tollefson, A. E., and
Wold, W. S. (2000). Tumor-specific, replication-competent adenovirus
vectors overexpressing the adenovirus death protein. J. Virol. 74,
6147–6155.
frat, S., Fejer, G., Brownlee, M., and Horwitz, M. S. (1995). Prolonged
survival of pancreatic islet allografts mediated by adenovirus immu-
noregulatory transgenes. Proc. Natl. Acad. Sci. USA 92, 6947–6951.
frat, S., Serreze, D. V., Svetlanov, A., Post, C. M., Johnson, E. A., Herold,
K., and Horwitz, M. S. Submitted.
lsing, A., and Burgert, H. G. (1998). The adenovirus E3/10.4K-14.5K
proteins down-modulate the apoptosis receptor Fas/Apo-1 by induc-
ing its internalization. Proc. Natl. Acad. Sci. USA 95, 10072–10077.
aber, P. W., Barnes, G. T., Srinidhi, J., Chen, J., Gusella, J. F., and
MacDonald, M. E. (1998). Huntington interacts with a family of WW
domain proteins. Hum. Mol. Genet. 7, 1463–1474.
riefeld, B. R., Lichy, J., Field, J., Gronostajski, R., Guggenheimer, R. A.,
Krevolin, M. D., Nagata, K., Hurwitz, J., and Horwitz, M. S. (1984). The
in vitro replication of adenovirus DNA in the molecular biology of
adenoviruses. In “Current Topics in Microbiology and Immunology”
(W. Doerfler, Ed.), pp. 221–255. Springer Verlag.
insberg, H. S., Moldawer, L. L., Sehgal, P. B., Redington, M., Kilian,
P. L., Chanock, R. M., and Prince, G. A. (1991). A mouse model for
investigating the molecular pathogenesis of adenovirus pneumonia.
Proc. Natl. Acad. Sci. USA 88, 1651–1655.
Ninsberg, H. S., and Prince, G. A. (1994). The molecular basis of
adenovirus pathogenesis [Review]. Infect. Agents Dis. 3, 1–8.
arrod, K. S., Hermiston, T. W., Trapnell, B. C., Wold, W. S. M., and
Whitsett, J. A. (1998). Lung-specific expression of adenovirus E3–
14.7K in transgenic mice attenuates adenoviral vector-mediated lung
inflammation and enhances transgene expression. Hum. Gene Ther.
9, 1885–1898.
irose, E., Nakashima, N., Sekiguchi, T., and Nishimoto, T. (1999). RagA
is a functional homologue of S. cerevisiae Gtr1p involved in the
Ran/Gsp1-GTPase pathway. J. Cell. Sci. 111: 11–21.
lan, Y., Droguett, G., RoyChowdhury, N., Li, Y., Sengupta, K., Thummala,
N. R., Davidson, A., RoyChowdhury, J., and Horwitz, M. S. (1997).
Insertion of the adenoviral E3 region into a recombinant viral vector
prevents antiviral humoral and cellular immune responses and per-
mits long term gene expression. Proc. Natl. Acad. Sci. USA 94,
2587–2592.
ackson, M. R., Nilsson, T., and Peterson, P. A. (1993). Retrieval of
transmembrane proteins to the endoplasmic reticulum. J. Cell Biol.
121, 317–333.
rajcsi, P., Dimitrov, T., Hermiston, T. W., Tollefson, A. E., Ranheim, T. S.,
Vande Pol, S. B., Stephenson, A. H., and Wold, W. S. (1996). The
adenovirus E3–14.7K protein and the E3–10.4K/14.5K complex of
proteins, which independently inhibit tumor necrosis factor (TNF)-
induced apoptosis, also independently inhibit TNF-induced release
of arachidonic acid. J. Virol. 70, 4904–4913.
eibowitz, G., Beattie, G. M., Kafri, T., Cirulli, V., Lopez, A. D., Hayek, A.,
and Levine, F. (1999). Gene transfer to human pancreatic endocrine
cells using viral vectors. Diabetes 48, 745–753.
eonard, G. T., and Sen, G. C. (1997). Restoration of interferon re-
sponses of adenovirus E1A-expressing HT1080 cell lines by overex-
pression of p48 protein. J. Virol. 71, 5095–5101.
i, Y., Kang, J., Friedman, J., Tarassishin, L., Ye, J., Kovalenko, A., Wallach,
D., and Horwitz, M. S. (1999). Identification of a cell protein (FIP-3) as
a modulator of NF-kappaB activity and as a target of an adenovirus
inhibitor of tumor necrosis factor alpha-induced apoptosis. Proc.
Natl. Acad. Sci. USA 96, 1042–1047.
i, Y., Kang, J., and Horwitz, M. S. (1998). Interaction of an adenovirus
E3–14.7kDa protein with a novel TNF-alpha inducible cellular protein
containing leucine zipper domains. Mol. Cell. Biol. 18, 1601–1610.
i, Y., Kang, J., and Horwitz, M. S. (1997). Interaction of an adenovirus
14.7kDa protein inhibitor of TNF-alpha cytolysis with a new member
of the GTPase superfamily of signal transducers. J. Virol. 71, 1576–
1582.
uftig, R. B., and Weihing, R. R. (1975). Adenovirus binds to rat brain
microtubules in vitro. J. Virol. 16, 696–706.
ukashok, S., and Horwitz, M. S. (1997). Adenovirus persistence. In
“Persistent Viral Infections” (R. Ahmed and I. Chen, Eds.), pp. 147–
164. Wiley, England.
ukashok, S. A., and Horwitz, M. S. (1998). New perspectives in adeno-
viruses. Curr. Clin. Top. Infect. Dis. 18, 286–305.
ukashok, S. A., Tarassishin, L., Li, Y., and Horwitz, M. S. (2000). An
adenovirus inhibitor of tumor necrosis factor alpha-induced apopto-
sis complexes with dynein and a small GTPase. J. Virol. 74, 4705–
4709.
ahr, J. A., and Gooding, L. R. (1999). Immune evasion by adenoviruses.
Immunol. Rev. 168, 121–130.
artin, M. E., and Berk, A. J. (1998). Adenovirus E1B 55K represses p53
activation in vitro. J. Virol. 72, 3146–3154.
athews, M. B., and Shenk, T. (1991). Adenovirus virus-associated RNA
and translation control [Review]. J. Virol. 65, 5657–5662.
ay, M. J., D’Acquisto, F., Madge, L. A., Glockner, J., Pober, J. S., and
Ghosh, S. (2000). Selective inhibition of NF-kappaB Activation by a
peptide that blocks the interaction of NEMO with the IkappaB kinase
complex. Science 289, 1550–1554.akaji, T., Kataoka, T. R., Watabe, K., Nishiyama, K., Nojima, H., and
Shimada, Y. (1999). A new member of the GTPase superfamily that is
SS
S
S
T
T
T
V
v
v
8 MINIREVIEWupregulated in highly metastatic cells. Cancer Lett. 147(1–2), 139–
147.
Nakashima, N., Noguchi E., and Nishimoto, T. (1999). Saccharomyces
cerevisiae putative G protein, Gtr1p, which forms complexes with
itself and a novel protein designated as Gtr2p, negatively regulates
the Ran/Gsp1p G protein cycle through Gtr2p. Genetics 153(3), 853–
867.
Oldstone, M. B., Nerenberg, M., Southern, P., Price, J., and Lewicki, H.
(1991). Virus infection triggers insulin-dependent diabetes mellitus in
a transgenic model: role of anti-self (virus) immune response. Cell
65, 319–331.
Perez, D., and White, E. (1998). E1B 19K inhibits Fas-mediated apopto-
sis through FADD-dependent sequestration of FLICE. J. Cell Biol. 141,
1255–1266.
Poller, W., Schneider-Rasp, S., Liebert, U., Merklein, F., Thalheimer, P.,
Haack, A., Schwaab, R., Schmitt, C., and Brackmann, H. H. (1996).
Stabilization of transgene expression by incorporation of E3 region
genes into an adenoviral factor IX vector and by transient anti-CD4
treatment of the host. Gene Ther. 3, 521–530.
Rigamonti, D., Bauer, J. H., De Fraja, C., Conti, L., Sipione, S., Sciorati,
C., Clementi, E., Hackam, A., Hayden, M. R., Li, Y., Cooper, J. K., Ross,
C. A., Govoni, S., Vincenz, C., and Cattaneo, E. (2000). Wild-type
huntingtin protects from apoptosis upstream of caspase-3. J. Neuro-
sci. 20, 3705–3713.
Rothwarf, D. M., Zandi, E., Natoli, G., and Karin, M. (1998). IKK-gamma
is an essential regulatory subunit of the IkappaB kinase complex
[see comments]. Nature 395, 297–300.
Schurmann, A., Brauers, A., Mabmann, S., Becker, W., and Joost, H. G.
(1995). Cloning of a novel family of mammalian GTP-binding proteins
(RagA, RagBs, RagB1) with remote similarity to the Ras-related
GTPases. J. Biol. Chem. 270, 28982–28988.
chwamborn, K., Weil, R., Courtois, G., Whiteside, S. T., and Israel, A.
(2000). Phorbol esters and cytokines regulate the expression of the
NEMO-related protein, a molecule involved in a NF-kappa B-inde-
pendent pathway. J. Biol. Chem. 275, 22780–22789.
henk, T. (1996). Adenoviridae: The viruses and their replication. In
“Fields Virology” (B. N. Fields, D. M. Knipe, and P. M. Howley, Eds.),
pp. 2111–2148. Lippincott-Raven, Philadelphia.
hisler, J., Yang, C., Walter, B., Ware, C. F., and Gooding, L. R. (1997). The
adenovirus E3–10.4K/14.5K complex mediates loss of cell surface Fas
(CD95) and resistance to Fas-induced apoptosis. J. Virol. 71, 8299–8306.
parer, T., Tripp, R. A., Dilleha, D. L., Hermiston, T. W., Wold, W. S., and
Gooding, L. R. (1996). The role of human adenovirus early region 3
proteins (gp19K, 10.4K, 14.5K and 14.7K) in a murine pneumonia
model. J. Virol. 70, 2431–2439.ollefson, A. E., Hermiston, T. W., Lichtenstein, D. L., Colle, C. F., Tripp,
R. A., Dimitrov, T., Toth, K., Wells, C. E., Doherty, P. C., and Wold, W. S.(1998). Forced degradation of Fas inhibits apoptosis in adenovirus-
infected cells. Nature 392, 726–730.
ollefson, A. E., Ryerse, J. S., Scaria, A., Hermiston, T. W., and Wold, W. S.
(1996). The E3–11.6-kDa adenovirus death protein (ADP) is required
for efficient cell death: Characterization of cells infected with adp
mutants. Virology 220, 152–162.
ollefson, A. E., Scaria, A., Hermiston, T. W., Ryerse, J. S., Wold, L. J., and
Wold, W. S. M. (1996). The adenovirus death protein (E3–11.6K) is
required at very late stages of infection for efficient cell lysis and
release of adenovirus from infected cells. J. Virol. 70, 2296–2306.
an Antwerp, D. J., Martin, S. J., Kafri, T., Green, D. R., and Verma, I. M.
(1996). Suppression of TNF-alpha-induced apoptosis by NF-kappaB
[see comments]. Science 274, 787–789.
an der Eb, A. J., Mulder, C., Graham, F. L., and Houweling, A. (1977).
Transformation with specific fragments of adenovirus DNAs. I. Iso-
lation of specific fragments with transforming activity of adenovirus 2
and 5 DNA. Gene 2, 115–132.
on Herrath, M., Efrat, S., Oldstone, M. B. A., and Horwitz, M. S. (1997).
Expression of adenoviral E3 transgenes in b cells prevents autoim-
mune diabetes. Proc. Natl. Acad. Sci. USA 94, 9808–9813.
Wang, E. W., Scott, M. O., and Ricciardi, R. P. (1988). An adenovirus
mRNA which codes a 14,700-Mr protein that maps to the last open
reading frame of region E3 is expressed during infection. J. Virol.
62(4), 1456–1459.
White, E. (1998). Regulation of apoptosis by adenovirus E1A and E1B
oncogenes. Semin. Virol. 8, 505–513.
Wold, W. S., Doronin, K., Toth, K., Kuppuswamy, M., Lichtenstein, D. L.,
and Tollefson, A. E. (1999). Immune responses to adenoviruses: Viral
evasion mechanisms and their implications for the clinic. Curr. Opin.
Immunol. 11, 380–386.
Wold, W. S. M., Tollefson, A. E., and Hermiston, T. W. (1995). The E3
transcription unit of adenovirus. In “The Molecular Repertoire of
Adenoviruses in Current Topics in Microbiology and Immunology”
(W. Doerfler, Ed.), pp. 237–274. Springer Verlag.
Yamaoka, S., Courtois, G., Bessia, C., Whiteside, S. T., Weil, R., Agou, F.,
Kirk, H. E., Kay, R. J., and Israel, A. (1998). Complementation cloning
of Nemo, a component of the IkB kinase complex essential for NF-kB
activation. Cell 93, 1231–1240.
Ye, J., Xie, X., Tarassishin, L., and Horwitz, M. S. (2000). Regulation of the
NF-kappaB activation pathway by isolated domains of FIP3/IKK-
gamma, a component of the IkappaB–alpha kinase complex. J. Biol.
Chem. 275, 9882–9889.
Zhang, S. Q., Kovalenko, A., Cantarella, G., and Wallach, D. (2000).
Recruitment of the IKK signalosome to the p55 TNF receptor: RIP and
A20 bind to NEMO (IKKgamma) upon receptor stimulation. Immunity
12, 301–311.
